Eleftherios S Xenos1, George A Davis2, Qiang He3, Amanda Green3, Susan S Smyth4. 1. Department of Surgery, Section of Vascular Surgery, University of Kentucky Medical Center, UK HealthCare, Lexington, Ky. Electronic address: esxeno2@email.uky.edu. 2. Pharmacy Services, The Gill Heart and Vascular Institute, University of Kentucky Medical Center, UK HealthCare, Lexington, Ky. 3. Office of Enterprise Quality and Safety, University of Kentucky Medical Center, UK HealthCare, Lexington, Ky. 4. Division of Cardiovascular Medicine, The Gill Heart and Vascular Institute, University of Kentucky Medical Center, UK HealthCare, Lexington, Ky.
Abstract
BACKGROUND: Massive and submassive pulmonary embolism (PE) can be life-threatening. Treatment options include anticoagulation, fibrinolysis, catheter-directed or open surgical thrombus removal, and extracorporeal membrane oxygenation. With increasing patient complexity and advanced therapeutic options, the approach to optimal care for patients with intermediate- to high-risk PE is not clearly established. Multidisciplinary, rapid response teams can optimize risk stratification and expedite management. A PE response team (PERT) composed of specialists from cardiology, vascular surgery, emergency medicine, pulmonary and critical care, interventional radiology, cardiac surgery, hospital medicine, and pharmacy was created at our institution. The team is tasked with evaluating and treating patients with massive and submassive PE by use of a risk stratification and treatment algorithm. We describe our initial experience with this approach. METHODS: The records of patients treated by the PERT since inception in October 2015 through May 2017 were reviewed (intervention group). The diagnoses codes of the PERT patients were retrieved from the Vizient database. A retrospective control cohort group was created using these specific diagnoses and a matching set of demographics (age, sex), Medicare Severity Diagnosis Related Group, admission severity of illness, and admission risk of mortality. Statistical analysis was performed using the Fisher exact test, the Pearson χ2 statistic, Student t-test, and Cochran-Cox approximation. P < .05 was considered significant. RESULTS: During the time interval, 77 patients with massive or submassive PE were treated by PERT activation; 992 patients included in the control group were treated at the discretion of an attending physician without use of the algorithm from October 2013 to 2016. Both groups had similar demographics, similar distribution of risk of mortality and severity of illness, and similar average Medicare Severity Diagnosis Related Group weighting. There was no statistically significant difference in the mortality rate between the two groups. The PERT group had significantly lower intensive care unit stay and overall length of stay. No difference was seen in direct cost between the two groups despite higher use of interventional treatment modalities in the PERT group. CONCLUSIONS: In our institution, assembly of a dedicated team to treat patients with massive or submassive PE according to a clinical algorithm resulted in expedited treatment and reduced variation of care. Intensive care unit stay and overall length of stay were reduced by this approach, with no impact on direct cost despite the use of advanced modalities of treatment. We believe that this paradigm can be of potential value in other disease entities, particularly when multiple disciplines are involved.
BACKGROUND: Massive and submassive pulmonary embolism (PE) can be life-threatening. Treatment options include anticoagulation, fibrinolysis, catheter-directed or open surgical thrombus removal, and extracorporeal membrane oxygenation. With increasing patient complexity and advanced therapeutic options, the approach to optimal care for patients with intermediate- to high-risk PE is not clearly established. Multidisciplinary, rapid response teams can optimize risk stratification and expedite management. A PE response team (PERT) composed of specialists from cardiology, vascular surgery, emergency medicine, pulmonary and critical care, interventional radiology, cardiac surgery, hospital medicine, and pharmacy was created at our institution. The team is tasked with evaluating and treating patients with massive and submassive PE by use of a risk stratification and treatment algorithm. We describe our initial experience with this approach. METHODS: The records of patients treated by the PERT since inception in October 2015 through May 2017 were reviewed (intervention group). The diagnoses codes of the PERT patients were retrieved from the Vizient database. A retrospective control cohort group was created using these specific diagnoses and a matching set of demographics (age, sex), Medicare Severity Diagnosis Related Group, admission severity of illness, and admission risk of mortality. Statistical analysis was performed using the Fisher exact test, the Pearson χ2 statistic, Student t-test, and Cochran-Cox approximation. P < .05 was considered significant. RESULTS: During the time interval, 77 patients with massive or submassive PE were treated by PERT activation; 992 patients included in the control group were treated at the discretion of an attending physician without use of the algorithm from October 2013 to 2016. Both groups had similar demographics, similar distribution of risk of mortality and severity of illness, and similar average Medicare Severity Diagnosis Related Group weighting. There was no statistically significant difference in the mortality rate between the two groups. The PERT group had significantly lower intensive care unit stay and overall length of stay. No difference was seen in direct cost between the two groups despite higher use of interventional treatment modalities in the PERT group. CONCLUSIONS: In our institution, assembly of a dedicated team to treat patients with massive or submassive PE according to a clinical algorithm resulted in expedited treatment and reduced variation of care. Intensive care unit stay and overall length of stay were reduced by this approach, with no impact on direct cost despite the use of advanced modalities of treatment. We believe that this paradigm can be of potential value in other disease entities, particularly when multiple disciplines are involved.
Authors: Christine M Groth; Nicole M Acquisto; Colin Wright; Mark Marinescu; Scott McNitt; Ilan Goldenberg; Scott J Cameron Journal: J Am Coll Clin Pharm Date: 2021-11-22
Authors: Romain Chopard; Umberto Campia; Lucas Morin; Karola S Jering; Zaid I Almarzooq; Julia Elizabeth Snyder; Samantha Rizzo; Aaron B Waxman; Samuel Z Goldhaber; Gregory Piazza Journal: J Thromb Thrombolysis Date: 2022-09-03 Impact factor: 5.221
Authors: Yu Lin Chen; Colin Wright; Anthony P Pietropaoli; Ayman Elbadawi; Joseph Delehanty; Bryan Barrus; Igor Gosev; David Trawick; Dhwani Patel; Scott J Cameron Journal: J Thromb Thrombolysis Date: 2020-01 Impact factor: 2.300
Authors: Brett J Carroll; Sebastian E Beyer; Tyler Mehegan; Andrew Dicks; Abby Pribish; Andrew Locke; Anuradha Godishala; Kevin Soriano; Jaya Kanduri; Kelsey Sack; Inbar Raber; Cara Wiest; Isabel Balachandran; Mason Marcus; Louis Chu; Margaret M Hayes; Jeff L Weinstein; Kenneth A Bauer; Eric A Secemsky; Duane S Pinto Journal: Am J Med Date: 2020-05-19 Impact factor: 4.965
Authors: Lukasz A Myc; Jigna N Solanki; Andrew J Barros; Nebil Nuradin; Matthew G Nevulis; Kranthikiran Earasi; Emily D Richardson; Shawn C Tsutsui; Kyle B Enfield; Nicholas R Teman; Ziv J Haskal; Sula Mazimba; Jamie L W Kennedy; Andrew D Mihalek; Aditya M Sharma; Alexandra Kadl Journal: Respir Res Date: 2020-06-22
Authors: Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang Journal: Blood Adv Date: 2020-10-13
Authors: Rachel P Rosovsky; Charles Grodzin; Richard Channick; George A Davis; Jay S Giri; James Horowitz; Christopher Kabrhel; Robert Lookstein; Geno Merli; Timothy A Morris; Belinda Rivera-Lebron; Victor Tapson; Thomas M Todoran; Aaron S Weinberg; Kenneth Rosenfield Journal: Chest Date: 2020-08-27 Impact factor: 9.410